✓ Medically reviewed by · Last reviewed: May 2026
Pharmacy Researcher · 8 years experience
Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.
Key takeaways
- Selank is a Russian-developed synthetic tuftsin analogue. The tetrapeptide tuftsin core has Pro-Gly-Pro added for enzymatic stability, producing a heptapeptide that crosses the blood-brain barrier.
- Anxiolytic mechanism without benzodiazepine-class side effects. GABA-system modulation plus enkephalinase effects — produces anxiety reduction without sedation, dependence, or cognitive impairment.
- Russian MoH registered for generalised anxiety disorder. No Western regulatory approval.
- Most-published route is intranasal, which dominates Russian clinical-research applications. Subcutaneous is the Western mechanism-research route.
- This guide covers mechanism, Russian regulatory context, and where Selank fits in anxiolysis research.
Selank Peptide: Russian-Developed Anxiolytic Tuftsin Analogue Research Guide
Selank is one of the two best-known Russian regulatory peptides on the catalogue (the other being Semax). The molecule produces anxiolytic effects through GABA-system modulation but without the sedation, dependence, or cognitive-impairment profile typical of benzodiazepine-class anxiolytics. For research-protocol design where non-benzodiazepine GABA-system mechanism is needed, Selank is the canonical research-grade option.
What is Selank
Selank (CAS 129954-34-3) is a synthetic heptapeptide built around the tuftsin core. Tuftsin is a tetrapeptide (Thr-Lys-Pro-Arg) cleaved from the heavy chain of IgG with both immunomodulatory and CNS activity. Native tuftsin is rapidly degraded in plasma by aminopeptidases. Selank extends the tuftsin core with C-terminal Pro-Gly-Pro — the same stability-engineering technique used in Semax — producing a heptapeptide with research-protocol-friendly half-life.
Mechanism
Selank acts as a GABA-system modulator with anxiolytic activity. Published mechanism research shows GABA receptor positive modulation along with effects on enkephalinase — the enzyme that degrades endogenous enkephalins (endogenous opioid peptides involved in mood regulation). The combination produces measurable anxiolytic effects in animal models and Russian clinical-research subjects, without the sedation, dependence, or cognitive-impairment profile of benzodiazepine-class GABA-receptor positive allosteric modulators.
The mechanistic distinctness from benzodiazepines is the defining feature. Benzodiazepines act as positive allosteric modulators of GABA-A receptors with broad CNS depression, sedation, and dependence liability. Selank’s GABA-system effects are more selective and don’t produce the broad CNS depression — the molecule is anxiolytic without being sedating or cognition-impairing.
Research applications
Primary applications: anxiety / anxiolysis research where non-benzodiazepine mechanism is the design constraint; GABA-system mechanism research; enkephalinase / endogenous-opioid research; stress-response neuroscience; generalised anxiety disorder research (the Russian-registered indication); and combined cognitive + anxiolysis research paired with Semax (the cognitive-arm complement).
Research dosing
Intranasal: 300-1200 mcg daily (typical dose ranges from published Russian and Western research). Subcutaneous: similar dose ranges. The molecule is split between single-daily and twice-daily administration patterns depending on the endpoint. Intranasal is the route used in the Russian-registered finished product; subcutaneous is more common in Western mechanism-research applications.
Side-effect profile
Favourable. No documented sedation, no cognitive impairment, no dependence liability. Russian published clinical-research data spans years of registered-product use with favourable safety signal. The main considerations are mild local irritation at the intranasal application site (transient) and the general consideration that Western pharmacovigilance documentation does not exist at the scale of Russian registered-product use.
Comparator and stacking
The most-paired stack partner is Semax, the cognitive-arm complement — see Selank vs Semax for the side-by-side comparison and the dual-arm protocol logic. For full cluster context see Best nootropic peptides.
Storage and reconstitution
Lyophilized vials at -20 °C long-term, 2-8 °C working stock. Reconstitute with bacteriostatic water or appropriate intranasal-spray vehicle. Reconstituted solution at 2-8 °C with use within ~30 days; protect from light; never freeze-thaw.
Safety and regulatory status
Selank is registered by the Russian Ministry of Health as a finished pharmaceutical product for generalised anxiety disorder. No FDA / EMA / MHRA approval. The research-grade compound on the catalogue is the same molecule as the Russian registered product but is not the registered finished product — it is sold for in-vitro laboratory research and analytical reference use only. None of this constitutes medical advice.
FAQ
How is Selank different from benzodiazepines?
Both have GABA-system mechanism arms, but Selank produces anxiolysis without sedation, dependence, or cognitive impairment. Benzodiazepines act as positive allosteric modulators of GABA-A receptors with broad CNS depression. Selank’s GABA-system effects are more selective and don’t produce the broad CNS depression — the molecule is anxiolytic without the trade-offs.
What’s the Pro-Gly-Pro extension for?
Enzymatic stability. The native tuftsin tetrapeptide is rapidly degraded in plasma by aminopeptidases. Adding Pro-Gly-Pro to the C-terminus blocks the cleavage site, extending half-life from minutes to a clinical-research-protocol-friendly window. Same technique is used in Semax.
Can Selank be used long-term?
Russian published clinical-research data spans years of registered-product use with favourable safety signal at the registered doses. The published research safety profile supports extended use; absence of Western pharmacovigilance at scale means long-term safety in unstudied populations carries more uncertainty than for FDA-approved comparator drugs.
What’s the typical research dose?
Intranasal 300-1200 mcg daily; subcutaneous similar dose ranges. The published research is split between single-daily and twice-daily administration patterns.
How does Selank compare to Semax?
Different parent peptides, different mechanism, different endpoints. Semax is the attention / cognitive-performance compound (BDNF / NGF + dopaminergic). Selank is the anxiolytic compound (GABA + enkephalinase). The two are often paired in research designs that need both arms.
Storage protocol?
Lyophilized at -20 °C long-term, 2-8 °C working; reconstituted at 2-8 °C use within 30 days; protect from light; never freeze-thaw.
Bottom line
Selank is the Russian-developed anxiolytic peptide that produces measurable anxiolytic effects via GABA-system modulation without the benzodiazepine-class side-effect profile (no sedation, no dependence, no cognitive impairment). For research-protocol design requiring non-benzodiazepine anxiolytic mechanism, Selank is the canonical research-grade option. The Russian Ministry of Health registration provides regulatory-precedent data without Western regulatory approval. Most commonly paired with Semax for dual-arm cognition + anxiolysis research.
Related research guides
Written by
Sophie ChenPharmaceutical Content Researcher · 8 years experience
Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.